The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

The Product Shortage PLUS Endorsement was developed in consultation with Cell One Partners Inc., a world leader in helping cell and gene therapy companies advance and achieve growth objectives toward ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

Last May, people were thrilled to learn that a 7-month-old baby who became the first in the world to receive a personalized ...

The cell and gene therapy quality control market size is calculated at USD 2.87 billion in 2025 and is expected to reach ...

About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...